Results to be presented during the tumor biology session at the ASCO
2018 Annual Meeting
Company Website:
http://www.nanthealth.com
CHICAGO -- (Business Wire)
NantWorks,
LLC today announced that its affiliate companies, NantHealth,
Inc., (NASDAQ: NH), a leading next-generation, evidence-based,
personalized healthcare company and NantOmics,
LLC, the leader in molecular analysis and a member of the NantWorks
ecosystem of companies, will present findings on how targeting immune
checkpoints and employing combinations has led to clinical benefit
across a variety of tumor types during the tumor biology sessionat
the American
Society of Clinical Oncology (ASCO) 2018 Annual Meeting, an event
bringing together 30,000 oncology professionals from June 1-5, 2018 at
McCormick Place in Chicago, Illinois. NantWorks will be exhibiting at
booth #7147 during the event.
“We are excited to share data on how profiling the tumor and associated
microenvironment can help tailor rational combinations of
immunotherapeutic strategies,” said Patrick Soon-Shiong, MD, founder of
NantWorks. “This data is an important step in enhancing response rates
through individualized immune checkpoints in PD-L1 expression, and we
look forward to continued exploration and potential solutions for
patients.”
Presentation Details
Co-expression
patterns of immune checkpoint molecules in relation to PD-L1 expression,
Abstract #12113
WHO: NantHealth, LLC and NantOmics, LLC
WHAT:
Tumor Biology Session
WHEN: June 4, 1:15-4:45 PM CST
WHERE:
Hall A, McCormick Place
Presentation Summary
In order to determine if tailored rational combinations of
immunotherapeutic strategies can be achieved by profiling the tumor and
associated microenvironment, whole transcriptomic sequencing of 1,880
unselected clinical cases, reflecting 38 distinct histologies, was
performed. Cases were categorized as PD-L1-low, PD-L1-normal and
PD-L1-high by cutoffs defined in TCGA expression profiles. The results
found that high and low PD-L1 expression in the tumor and adjacent
microenvironment are associated with variations in key checkpoint
molecules. The results also found that low expression of PD-L1 may be an
ideal setting for use of IDO- or TIM3-directed therapies.
About NantHealth, Inc.
NantHealth, Inc., a member of the NantWorks ecosystem of companies, is a
next-generation, evidence-based, personalized healthcare company
enabling improved patient outcomes and more effective treatment
decisions for critical illnesses. NantHealth's unique systems-based
approach to personalized healthcare applies novel diagnostics tailored
to the specific molecular profiles of patient tissue and integrates this
molecular data in a clinical setting with large-scale, real-time
biometric signal and phenotypic data to track patient outcomes and
deliver precision medicine. For nearly a decade, NantHealth has
developed an adaptive learning system that integrates our unique
molecular profiling solution, software and hardware. Our system
infrastructure collects, indexes, analyzes and interprets billions of
molecular, clinical, operational and financial data points derived from
novel and traditional sources to continuously improve decision-making
and optimize our clinical pathways and decision algorithms over time.
For more information please visit www.nanthealth.com.
About NantOmics
NantOmics, a member of the NantWorks ecosystem of companies, delivers
molecular analysis capabilities with the intent of providing actionable
intelligence and molecularly driven decision support for cancer patients
and their providers at the point of care. NantOmics is the first
molecular analysis company to pioneer an integrated approach to
unearthing the genomic and proteomic variances that initiate and drive
cancer, by analyzing both normal and tumor cells from the same patient
and following identified variances through from DNA to RNA to protein to
drug. NantOmics has a highly scalable cloud-based infrastructure capable
of storing and processing thousands of genomes a day, computing genomic
variances in near real-time, and correlating proteomic pathway analysis
with quantitative multi-plexed protein expression analysis from the same
micro-dissected tumor sample used for genomic analysis. For more
information please visit www.nantomics.com and
follow Dr. Soon-Shiong on Twitter @DrPatSoonShiong.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180602005097/en/
Contacts:
NANT
Jen Hodson
jhodson@nantworks.com
or
NANT
Henry
C. Jackson
cj@nantworks.com
Source: NantHealth, Inc.
© 2024 Canjex Publishing Ltd. All rights reserved.